NephroCheck

NephroCheck is a diagnostic test used to assess the risk of Acute Kidney Injury (AKI) in critically ill patients. The test measures the levels of two biomarkers, Insulin-like growth factor-binding protein 7 (IGFBP7) and Tissue inhibitor of metalloproteinases-2 (TIMP-2), in the urine. High levels of these biomarkers indicate a higher risk of AKI.

Overview

NephroCheck is a diagnostic test that measures the levels of two biomarkers, IGFBP7 and TIMP-2, in the urine. These biomarkers are proteins that are produced by cells in response to stress. When the kidneys are stressed, such as during a critical illness or after major surgery, the levels of these biomarkers in the urine can increase. By measuring the levels of these biomarkers, the NephroCheck test can help doctors assess the risk of AKI in critically ill patients.

Test Procedure

The NephroCheck test is a urine test. A sample of the patient's urine is collected and sent to a laboratory. The laboratory uses a special machine to measure the levels of the IGFBP7 and TIMP-2 biomarkers in the urine. The results of the test are usually available within a few hours.

Interpretation of Results

The results of the NephroCheck test are given as a score, known as the AKI Risk Score. This score is calculated based on the levels of the IGFBP7 and TIMP-2 biomarkers in the urine. A higher score indicates a higher risk of AKI.

Clinical Significance

The NephroCheck test can help doctors identify patients who are at risk of developing AKI. This can allow for earlier intervention and potentially prevent the development of AKI. However, the test is not a definitive diagnosis of AKI and should be used in conjunction with other clinical information.

See Also

• Acute Kidney Injury
• Biomarker
• Insulin-like growth factor-binding protein 7
• Tissue inhibitor of metalloproteinases-2

References

NephroCheck Resources
Latest articles Most recent articles Ongoing trials	Wikipedia